Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

643
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
643

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms.

JCO oncology practice·2026
Same author

Differential stem-like potential of naïve and memory CD8 T cells after chronic infection.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

The evolving role of cytokines for CAR-T cell manufacturing and beyond.

Nature biomedical engineering·2026
Same author

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

"Protected time" for clinical investigators in medical oncology: The persistent gap between expectation and reality.

Cancer·2026
Same author

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variants.

mAbs·2026

Related Experiment Video

Updated: Aug 27, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K

PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program.

Masao Hashimoto1,2, Koichi Araki1,2,3,4, Maria A Cardenas5

  • 1Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.

Nature
|September 28, 2022
PubMed
Summary
This summary is machine-generated.

Combining PD-1 blockade and IL-2 therapy reshapes stem-like CD8+ T cells into potent effectors, enhancing viral control. This synergy, driven by IL-2 signaling via CD25, offers insights for cancer immunotherapy.

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K
Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

406

Related Experiment Videos

Last Updated: Aug 27, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.1K
Measuring Mitochondrial Function of Na&#239;ve and Effector CD8 T Cells
06:07

Measuring Mitochondrial Function of Naïve and Effector CD8 T Cells

Published on: March 28, 2025

406

Area of Science:

  • Immunology
  • Virology
  • T cell biology

Background:

  • Combination therapy with PD-1 blockade and IL-2 is effective against chronic lymphocytic choriomeningitis virus.
  • Understanding the synergistic mechanisms is crucial for optimizing cancer immunotherapies.

Purpose of the Study:

  • To elucidate the underlying mechanisms of synergy between PD-1 blockade and IL-2 therapy.
  • To investigate how this combination therapy impacts T cell differentiation and function.

Main Methods:

  • Analysis of PD-1+TCF1+ stem-like CD8+ T cell differentiation programs.
  • Assessment of transcriptional and epigenetic changes in effector CD8+ T cells.
  • Investigation of IL-2 receptor (CD25, CD122, CD132) expression and function.
  • Utilizing CD25 blocking antibodies and mutated IL-2 to probe CD25's role.

Main Results:

  • PD-1 + IL-2 combination therapy generates superior effector CD8+ T cells, unlike PD-1 monotherapy.
  • Stem-like CD8+ T cells are not terminally exhausted and can be redirected by IL-2.
  • IL-2-induced synergy relies on IL-2 binding to CD25, enhancing the IL-2 receptor complex.
  • Blocking CD25 or using CD25-nonbinding IL-2 abrogates the synergistic effects.

Conclusions:

  • IL-2 synergizes with PD-1 blockade by altering the differentiation of stem-like CD8+ T cells into highly functional effectors.
  • CD25 engagement by IL-2 is critical for this synergy, highlighting a key target for immunotherapy.
  • These findings provide a mechanistic basis for the efficacy of PD-1 + IL-2 combination therapy and inform its application in cancer treatment.